Isogenica announced today that Dr William (Bill) Eldridge has been promoted to Chief Scientific Officer. Since joining Isogenica as Senior Director of Antibody Alliances in January 2020, Dr Eldridge has played a leading role in delivering Isogenica’s multi-target...
Isogenica multi-year multi-target collaboration with Aro Biotherapeutics extended Isogenica-Aro collaboration goes from strength to strength Read The Press Release Isogenica today announced the collaboration and license agreement signed with Aro Biotherapeutics in...
Isogenica Pre-doc Program Isogenica is excited to announce the opening of a new Pre-doctoral program: a 1-year research program designed to provide meaningful, practical industry experience in preparation for a high-level graduate program. As a small but growing...
Isogenica supports MRC iCASE PhD Award The successful applicant will gain industry experience in single domain VHH antibody discovery at Isogenica and renowned haematology research labs of Professor Martin Dyer, University of Leicester This project provides an...
Isogenica announces leadership appointments Isogenica has made two leadership appointments to extend and accelerate its partnerships and pipeline of therapeutic assets and provide a strong foundation for Isogenica’s future growth Isogenica today announced that it has...
Isogenica announces multimillion-pound agreement with recently nasdaq listed BioNTech SE Isogenica multi-target, multi-year collaboration and license agreement with BioNTech SE Isogenica has entered into a multi-target, multi-year partnership with BioNTech. The...
